Newsroom | 25998 results
Sorted by: Latest
-
Passage of New Georgia Bill a Win for Farmers
ST. LOUIS--(BUSINESS WIRE)--Farmers and others in agriculture applaud Governor Brian Kemp and the Georgia General Assembly for supporting the crop protection tools so important to Georgia’s farmers’ ability to produce affordable, safe, abundant food. With Governor Kemp signing SB 144, Georgia has taken the step to re-affirm the authority of the U.S. Environmental Protection Agency’s (EPA) scientific rulings on the safety of crop protection products. “The signing of SB 144 by Governor Kemp demon...
-
Journal of Clinical Oncology Publishes Significant Evidence in Advancing Racial Equity in Cancer Care Through Artera's Multimodal AI Model
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced the publication of a validation study in the JCO Clinical Cancer Informatics on Artera’s MMAI model. The study assessed the ability of the MMAI model to perform similarly across racial subgroups using data from prostate cancer trials with diverse representation. AI tools are becoming instrumental in helping with clinical decision-making, but...
-
Epicrispr Biotechnologies Named Finalist in XPRIZE Healthspan Competition FSHD Bonus Prize
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epicrispr Biotechnologies Named Finalist in XPRIZE Healthspan Competition FSHD Bonus Prize...
-
Dr. Gloria Sheynkman from the University of Virginia to Present Pioneering Research utilizing Quantum-Si’s Next-Gen Protein Sequencing™ Platform in Upcoming Nature Webinar on May 15
BRANFORD, Conn.--(BUSINESS WIRE)--Dr. Gloria Sheynkman, University of Virginia, Presents Research utilizing Quantum-Si’s Next-Gen Protein Sequencing™ Platform in Nature Webinar on 5/15...
-
Aera Therapeutics Appoints Paul Conrad, Ph.D., MBA, as Chief Business and Financial Officer
BOSTON--(BUSINESS WIRE)--Aera Therapeutics, a biotechnology company harnessing next-generation enabling delivery technologies and precision payloads to unlock the full potential of genetic medicines, today announced the appointment of Paul Conrad, Ph.D., MBA, as chief business and financial officer. Dr. Conrad brings more than 30 years of biopharma experience and expertise spanning R&D, strategy and operations, business and corporate development, alliance management, and finance. “We are ex...
-
Redwire Corporation Reports First Quarter 2025 Financial Results
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Redwire Corporation (NYSE: RDW, “Redwire” or the “Company”), a leader in space infrastructure for the next generation space economy, today announced results for its first quarter ended March 31, 2025. Redwire will live stream a presentation with slides on May 12, 2025 at 9:00 a.m. ET. Please use the link below to follow along with the live stream: https://event.choruscall.com/mediaframe/webcast.html?webcastid=4F31SXFe “Bookings increased significantly compar...
-
Intrepid Labs Launches to Transform Drug Formulation with AI and Autonomous Labs
TORONTO--(BUSINESS WIRE)--Intrepid Labs’ Valiant platform uses AI and robotics to cut drug formulation timelines from months to days....
-
Rockwell Medical Announces First Quarter 2025 Results
WIXOM, Mich.--(BUSINESS WIRE)--Rockwell Medical announces financial and operational results for the three months ended March 31, 2025....
-
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at May 5, 2025: Total number of shares outstanding: 92,176,373 ordinary shares 6,489 Pre...
-
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Presents Positive Preclinical Data on ABCL575 at the SID Annual Meeting 2025...